Key clinical point: The improved progression-free survival seen with maintenance rucaparib vs. placebo in ARIEL3 occurred across age subgroups.
Major finding: PFS with rucaparib vs. placebo did not differ significantly across age subgroups (HR, 0.33, 0.43, 0.47 for those under age 65, aged 65-74, and 75+, respectively).
Study details: A post hoc analysis of data for 564 patients in the ARIEL3 study.
Disclosures: ARIEL3 was funded by Clovis Oncology. Dr. Ledermann reported financial relationships (consulting, grant receipt, honorarial reimbursement, and/or speakers bureau fees) with AstraZeneca, Clovis Oncology, Pfizer, Seattle Genetics, Roche, and MSD/Merck.
Ledermann J et al. SGO 2019, Abstract 4.